Organization | Evotec

Evotec Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Hamburg Germany (1993)

Organization Overview

First Clinical Trial

2006

NCT00380003

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evotec AG | Evotec Neurosciences GmbH

Active Ingredients

Drugs in Phase 3 Trials (10)

Key: Evotec (0) Acquired (10)

acetaminophen (tylenol) (1 trial)

bevacizumab (avastin) (1 trial)

birch allergen (1 trial)

cetuximab (erbitux) (1 trial)

codeine (Phenergan) (1 trial)

fluorouracil (efudex) (1 trial)

ibuprofen (motrin) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Drugs in Phase 2 Trials (7)

Key: Evotec (4) Acquired (3)

citalopram (celexa) (2 trials)

diapep277 (1 trial)

evt 201 (2 trials)

nicotine (nicorette) (2 trials)

rbet v1-fv (1 trial)

sembragiline (2 trials)

tacrolimus (prograf) (2 trials)

Drugs in Phase 1 Trials (4)

Key: Evotec (0) Acquired (4)

anle138b (3 trials)

fluvoxamine (luvox) (1 trial)

somatoprim (1 trial)

teicoplanin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Sleepiness (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 18
# of Trial APIs: 21